I would say that our goals are the same. It is to make sure that people can afford medication and that patients who have rare conditions that require extremely novel or very expensive therapeutics also have access. That is why we have two processes: the PMPRB review, as you know; and also the rare diseases strategy that's under development.
I am going to continue this path, Mr. Chair, to ensure that we can get to a place where people are not having to choose between paying rent and buying medication.